Differential effects of 5-fluorouracil on glucose transport and expressions of glucose transporter proteins in gastric cancer cells

Anti-Cancer Drugs

Volumn 21, Issue 3, 2010, Pages 270-276

  Won, Hye Jin ^a,b   Ha, Tae Kyung ^c   Kwon, Sung Joon ^c   Cho, Hong Yon ^a   Hur, Sook Jin ^c   Baik, Hyung Hwan ^d   Suh, Seong Il ^f   Ha, Eunyoung ^f   Kim, Yong Ho ^e  

^a Korea University   (South Korea)

^b Korea Food and Drug Administration   (South Korea)

^c Hanyang University   (South Korea)

^d Chungnam National University   (South Korea)

^e Kyung Hee University Hospital   (South Korea)

^f Keimyung University   (South Korea)

Author keywords

5 fluorouracil; Gastric cancer; Glucose transport

Indexed keywords

FLUOROURACIL; GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 2; GLUCOSE TRANSPORTER 3; GLUCOSE TRANSPORTER 4; GLYCOGEN SYNTHASE KINASE 3; HEXOKINASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL TYPE; CELL VIABILITY; CYTOTOXICITY; DRUG EFFECT; DRUG SENSITIVITY; FLUORESCENCE MICROSCOPY; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNET RING CARCINOMA; STOMACH ADENOCARCINOMA; STOMACH CANCER;

ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL TRANSPORT; CARCINOMA, SIGNET RING CELL; CELL LINE, TUMOR; FLUOROURACIL; GLUCOSE; GLUCOSE TRANSPORT PROTEINS, FACILITATIVE; GLYCOGEN SYNTHASE KINASE 3; HEXOKINASE; HUMANS; STOMACH NEOPLASMS;

EID: 76649096671     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328334562c     Document Type: Article

References (29)

1. Warburg O. On the origin of cancer cells. Science 1956; 123:309-314.
2. Beaney RP. Positron emission tomography in the study of human tumors. Semin Nucl Med 1984; 14:324-341.
3. Silverman D, Hor CK, Seltzer MA, Schiepers C, Cuan GS, Gambhir SS, et al. Evaluating tumor biology and oncological disease with positronemission tomography. Semin Radiat Oncol 1998; 8:183-196.
4. Yamada A, Oguchi K, Fukushima M, Imai Y, Kadoya M. Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in gastric carcinoma: relation to histological subtypes, depth of tumor invasion, and glucose transporter-1 expression. Ann Nucl Med 2006; 20:597-604.
5. Ajani JA. Evolving chemotherapy for advanced gastric cancer. Oncologist 2005; 10 (Suppl 3):49-58.
6. Jakobsen A, Nielsen JN, Gyldenkerne N, Lindeberg J. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 2005; 23:1365-1369.
7. Hwang JT, Ha J, Park OJ. Combination of 5-fluorouracil and genistein induces apoptosis synergistically in chemo-resistant cancer cells through the modulation of AMPK and COX-2 signaling pathways. Biochem Biophys Res Commun 2005; 332:433-440.
8. Suttie SA, Park KGM, Smith TAD. [18F]2-fluoro-2-deoxy-D-glucose incorporation by AGS gastric adenocarcinoma cells in vitro during response to epirubicin, cisplatin and 5-fluorouracil. Br J Cancer 2005; 97:902-909.
9. Fakhrejahani E, Miyamoto A, Tanigawa N. Correlation between thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level and in vitro chemosensitivity to 5-fluorouracil, in relation to differentiation in gastric cancer. Cancer Chemother Pharmacol 2007; 60:437-446.
10. Yamamoto T, Seino Y, Fukumoto H, Koh G, Yano H, Inagaki N, et al. Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun 1990; 170:223-230.
11. Nishioka T, Oda Y, Seino Y, Yamamoto T, Inagaki N, Yano H, et al. Distribution of the glucose transporters in human brain tumors. Cancer Res 1992; 52:3972-3979.
12. Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer 1993; 72:2979-2985.
13. Nagase Y, Takata K, Moriyama N, Aso Y, Murakami T, Hirano H. Immunohistochemical localization of glucose transporters in human renal cell carcinoma. J Urol 1995; 153:798-801.
14. Baer SC, Casaubon L, Younes M. Expression of the human erythrocyte glucose transporter Glut1 in cutaneous neoplasia. J Am Acad Dermatol 1997; 37:575-577.
15. Ogawa J, Inoue H, Koide S. Glucose-transporter-type-I-gene amplification correlates with sialyl-Lewis-X synthesis and proliferation in lung cancer. Int J Cancer 1997; 74:189-192.
16. Haber RS, Rathan A, Weiser KR, Pritsker A, Itzkowits SH, Bodian C, et al. GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer 1998; 83:34-40.
17. Wang BY, Kalir T, Sabo E, Sherman DE, Cohen C, Burstein DE. Immunohistochemical staining of GLUT1 in benign, hyperplastic, and malignant endometrial epithelia. Cancer 2000; 88:2774-2781.
18. Cantuaria G, Fagotti A, Ferrandina G, Magalhaes A, Nadji M, Angioli R, et al. GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy. Cancer 2001; 92:1144-1150.
19. Rudlowski C, Becker AJ, Schroder W, Rath W, Büttner R, Moser M. GLUT1 messenger RNA and protein induction relates to the malignant transformation of cervical cancer. Am J Clin Pathol 2003; 120:691-698.
20. Hakata T, Ito K, Horie T. Enhanced absorption of 3-O-methyl glucose following gastrointestinal injury induced by repeated oral administration of 5-FU in mice. J Pharm Sci 2005; 94:1713-1722.
21. Embi N, Rylatt DB, Cohen P. Glycogen synthase kianse-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem 1980; 107:519-527.
22. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003; 116:1175-1186.
23. Kockeritz L, Doble B, Patel S, Woodgett JR. Glycogen synthase kinase-3- an overview of an over-achieving protein kinase. Curr Drug Targets 2006; 7:1377-1388.
24. Buller CL, Loberg RD, Fan MH, Zhu Q, Park JL, Vesely E, et al. A GSK-3/ TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression. Am J Physiol Cell Physiol 2008; 295:C836-C843.
25. Ha E, Yim SV, Jung KH, Yoon SH, Zheng LT, Kim MJ, et al. Topiramate stimulates glucose transport through AMP-activated protein kinasemediated pathway in L6 skeletal muscle cells. Pharmacogenomics J 2007; 6:327-332.
26. Smith TAD, Sharma RI, Wang WG, Welch AE, Schweiger LF, Collie-Duguid ESR. Decreased [18F]fluoro-2-deoxy-D-glucose incorporation and increased glucose transport are associated with resistance to 5FU in MCF7 cells in vitro. Nucl Med Biol 2007; 34:955-960.
27. Marín-Hernández A, Rodríguez-Enríquez S, Vital-Gonzá lez PA, Flores-Rodríguez FL, Macías-Silva M, Sosa-Garrocho M, Moreno-Sánchez R. Determining and understanding the control of glycolysis in fast-growth tumor cells. Flux control by an over-expressed but strongly product-inhibited hexokinase. FEBS J 2006; 273:1975-1988.
28. Kawamura T, Kusakabe T, Sugino T, Watanabe K, Fukuda T, Nashimoto A, et al. Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer 2001; 92:634-641.
29. Grimes CA, Jope RS. The multifaceted roles of glycogen synthase kinase 3 beta in cellular signaling. Prog Neurobiol 2001; 65:391-426.